Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01367561 · ClinicalTrials.gov registry record · Phase 1
Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function
A Phase 1 study of Healthy Males, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
- 1
- Study location
NCT01367561 is a Phase 1 study of Healthy Males that has completed, run by Bausch Health Americas. The registered enrollment target is 15 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01367561, a Phase 1 study of Healthy Males, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a double-blind, randomized, study at a single clinical site investigating the effect of methylnaltrexone and naloxone versus placebo in healthy males who have received a short-acting opioid, remifentanil.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Naloxone
- DRUG IV Methylnaltrexone (MNTX)
Study Locations (1)
New York
- Progenics Pharmaceuticals, Inc. - Tarrytown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2002-10 |
| Est. Completion | 2003-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01367561
The ClinicalTrials.gov registry entry for NCT01367561 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Males appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT01367561 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT01367561 about?
NCT01367561 is a clinical study titled "Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function". This is a double-blind, randomized, study at a single clinical site investigating the effect of methylnaltrexone and naloxone versus placebo in healthy males who have received a short-acting opioid, remifentanil.
What is the current status of trial NCT01367561?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2002-10. Estimated completion is 2003-05.
What conditions does trial NCT01367561 study?
This clinical trial studies the following conditions: Healthy Males.
What interventions are being tested in trial NCT01367561?
The interventions under investigation include: Placebo (DRUG), Naloxone (DRUG), IV Methylnaltrexone (MNTX) (DRUG).
Who is sponsoring clinical trial NCT01367561?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01367561 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Males
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.